Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RWY-dL-(Gd-DOTA)4
- Development stage
- Preclinical
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Peptides, Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
RWY-dL-(Gd-DOTA)4 is a **peptide-based gadolinium chelate** designed for use as a contrast agent in **magnetic resonance imaging (MRI)**. The structure consists of a synthetic peptide (RWY-dL) conjugated to four gadolinium-DOTA complexes. DOTA (1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid) acts as a **macrocyclic chelator** that securely binds Gd3+ ions, increasing the safety and stability of the contrast agent. Such peptide-DOTA(Gd) constructs are used to enhance imaging specificity by targeting peptides to tumor tissues or specific biomarkers, while the gadolinium provides MRI signal enhancement. The mechanism relies on **targeted delivery via the peptide sequence and MRI signal sensitization via the Gd-DOTA moieties**. Similar entities have been investigated for their utility in preclinical tumor imaging and molecular imaging agent development[1][2][4].
- Other names
- RWY-dL-(Gd-DOTA)4
02
Targets
ITGA6 (Integrin alpha-6)
Beyond the preview
Go deeper on RWY-dL-(Gd-DOTA)4.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RWY-dL-(Gd-DOTA)4.